Bellicum Pharmaceuticals today announced the successful completion of a $55M Series C financing.
The financing will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor T cell and cancer vaccine product candidates in a variety of blood and solid tumor cancers, and in nonmalignant genetic diseases.
Eleven new investors participated in the financing round, including funds managed by RA Capital Management, LLC, Perceptive Advisors, LLC, Jennison Associates LLC , Sabby Capital, LLC, Ridgeback Capital Management, venBio Select, Redmile Group, LLC, AJU IB Investment and others.
All of the Company’s major current investors, including AVG Ventures and Remeditex Ventures, participated in the financing.
The Series C financing brings the total capital raised since inception to $107 million.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Finding Biopharma and Collaboration Partners
Related reports: Entire Current Partnering reports catalog
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering Insight Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity